Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/10—Laxatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/12—Antidiarrhoeals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/08—Drugs for disorders of the urinary system of the prostate
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

• the present invention relates to novel 4-arylmorpholin-3-one derivatives, their preparation and their therapeutic application.
• the compounds according to the present invention have a very high affinity for human NK2 receptors of neurokinin A.
• Neurokinin A belongs to a group of neuropeptides called tachykinins or neurokinins that includes substance P (SP) and neurokinin B (NKB).
• SP substance P
• NKB neurokinin B
• the biological effects of neurokinin A as well as other tachykinins are mediated by receptors specific to the G-protein-coupled seven-transmembrane receptor family that are named NK 1 , NK 2 and NK 3 .
• the tachykinin NK 2 receptor binds neurokinin A whereas the NK 1 and NK 3 receptors bind substance P and neurokinin B respectively (Pennefather JN et al., Life ScL, 2004, 74, 1445-1463).
• NK 2 receptors with tachykinins are very widely expressed in the peripheral nervous system, where they mediate the wide variety of effects produced by neurokinin A, especially and in a non-limiting way in the respiratory system (bronchoconstriction, cough, inflammation, bronchial hyperactivity (Joos GF, Handb., Exp Pharm., 2004, 164, 491-510, Advenier C. et al., Eur Respir J., 1997, K), 1892-1906), gastrointestinal (inflammation , infection, motility, pain, %) (Holzer P, Handb Exp Pharm., 2004,
• tachykinin NK 2 receptor is also expressed in the brain (Hagan RM et al., Regul Pept, 1993, 46, 9-19, Steinberg R. et al, Eur J. Neurosci., 1998, 10, 2337- 2345, Bensaid M. et al., Neurosci Lett, 2001, 303, 25-28;
• A may represent the divalent radical -O-CH 2 -CO-; Am, m, Ar 1 and T have different values.
• the compounds (A) have an affinity for the NK 1, NK 2 or NK 3 receptors of tachykinins in general.
• - DE may represent a divalent radical -O-CH 2 -CH 2 -;
• L, G, E, A, B, R a and R b have different values.
• Compounds (B) are antagonists of both NK4 receptors and NK2 receptors of tachykinins.
• the application WO 00/34274 relates to cyclohexylpiperidine derivatives which are antagonists of both the NKi receptors of the substance P and the NK2 receptors of the neurokinin A.
• the application WO 02/094821 relates to morpholine derivatives which are antagonists to both human NK2 receptors and human NK3 receptors for tachykinins.
• the compounds of the present invention exhibit good bioavailability when administered orally and pass the blood brain barrier.
• Ar represents a phenyl mono- or disubstituted with a halogen atom
• R 1 represents a phenyl that is unsubstituted or substituted one or two times with one or two substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy;
• R2 represents: pyridyl; phenyl which is unsubstituted or substituted one or two times with one or two substituents independently selected from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy, a trifluoromethyl group, a trifluoromethoxy group;
• a benzyl which is unsubstituted or substituted on the phenyl one or two times with one or two substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy, a trifluoromethyl group and a trifluoromethoxy group; ;
• R2 can further represent:
• a heterocyclic radical chosen from azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine or perhydroazepine when R3 represents a cyano or a -CONR 11R12 group;
• R3 represents a group chosen from:
• R 4 represents a (C 1 -C 4 ) alkyl; a (C 3 -C 7) cycloalkyl unsubstituted or substituted by one or more methyls; phenyl; pyridyl;
• R5 and Rg each independently represent a hydrogen atom or a (C -C 4) alkyl;
• R 6 may further represent (C 3 -C 7 ) cycloalkylmethyl, benzyl or phenyl; or R 5 and R 6 together with the nitrogen atom to which they are attached, constitute a heterocycle chosen from the azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine the perhydroazepine and piperazine which is unsubstituted or substituted in position 4 by a (C 1 -C 4 ) alkyl;
• R 7 represents a hydrogen atom or a (C 1 -C 4 ) alkyl
• Rg represents a hydrogen atom; a (Ci-C 4) alkyl; a vinyl; phenyl; benzyl; pyridyl; a (C 3 -C 7 ) cycloalkyl unsubstituted or substituted with one or more methyls; a furyle; thienyl; pyrrolyl; imidazolyl;
• R 7 and R 3 together represent a group - (CH 2 ) p-;
• R 9 is (C 1 -C 4 ) alkyl or phenyl
• R 7 and R 9 together represent a group - (CH 2 ) n -;
• n is 2 or 3;
• R 1 represents a (C 1 -C 4) alkyl; an amino which is free or substituted with one or two (C 1 -C 4) alkyls; a phenyl which is unsubstituted or substituted one or more times with a substituent chosen from: a halogen atom, a (C - [- C4) alkyl, a trifluoromethyl, a hydroxy, a (C 1 -C 4) alkoxy, a carboxy, a (C 1 -C 4) alkoxycarbonyl, a (C 1 -C 4) alkylcarbonyloxy, a cyano, a nitro, an amino free or substituted by one or two (C 1 -C 4) alkyls, said substituents being the same or different;
• R 1 and R 2 each independently represent a hydrogen or a
• R12 may further represent (C3-C7) cycloalkyl, (C3-C7) cycloalkylmethyl, hydroxy, (C1-C4) alkoxy, benzyl or phenyl; or Rn and R12 together with the nitrogen atom to which they are attached constitute a heterocycle selected from azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine or perhydroazepine;
• R7 and R12 together represent a group - (CH2) m -; m is 2 or 3;
• R 1 and R 4 each independently represent a hydrogen atom or a (C 1 -C 4) alkyl; R 1 may further represent a (C 3 -C 7) cycloalkylmethyl or benzyl;
• Ri 5 represents a hydrogen atom; a (C1-C4) alkyl; formyl; (C 1 -C 4) alkylcarbonyl;
• Ri g represents a (C 1 -C 4) alkoxy
• R 17 and R 18 each independently represent a hydrogen atom or a (C 1 -C 4) alkyl
• Ri 7 and Ri g together with the nitrogen atom to which they are attached constitute a heterocycle selected from pyrrolidine, piperidine or morpholine;
• R19 represents a hydrogen atom or a (C1-C4) alkyl
• R 20 and R 21 each independently represent a hydrogen atom or a (C 1 -C 4) alkyl; R21 may further represent formyl or (C1-C4) alkylcarbonyl.
• the compounds of formula (I) may comprise one or more asymmetric carbon atoms. They can therefore exist as enantiomers or diastereoisomers. These enantiomers, diastereoisomers and mixtures thereof, including racemic mixtures, form part of the invention.
• the compounds of formula (I) may exist in the form of bases or addition salts with acids. Such addition salts are part of the invention. These salts are advantageously prepared with pharmaceutically acceptable acids, but the salts of other acids that are useful for purifying or isolating the compounds of formula (I) are also part of the invention.
• the compounds of formula (I) may also exist in the form of hydrates or solvates, namely in the form of associations or combinations with one or more water molecules or with a solvent. Such hydrates and solvates are also part of the invention.
• halogen atom is meant a bromine, chlorine, fluorine or iodine atom.
• (C 1 -C 4) alkyl is meant a linear or branched alkyl radical of one to four carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, isobutyl, tert-butyl.
• alkoxy is meant a linear or branched alkoxy radical of one to four carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, butoxy-butoxy.
• cycloalkyl is meant a cyclic alkyl group of 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
• a first group of compounds is constituted by the compounds for which: - Ar represents a phenyl disubstituted by a halogen atom;
• R 1 represents a phenyl that is unsubstituted or substituted once or twice with a halogen atom
• R2 represents: pyridyl; . phenyl which is unsubstituted or substituted once or twice with one or two substituents independently selected from a halogen atom, a
• R 2 may further represent a heterocyclic radical selected from azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine or perhydroazetidine when R3 is -CONRi 1 R 12 ;
• R3 represents a group chosen from: (5) - (CH2) q -OH in which q is 0;
• R 1 represents a phenyl which is unsubstituted or substituted one or two times with a halogen atom
• R2 represents: pyridyl; . phenyl which is unsubstituted or substituted once or twice with one or two substituents independently selected from a halogen atom, a
• R2 may further represent a heterocyclic radical selected from azetidine, pyrrolidine, piperidine, morpholine, thiomorpholine or perhydroazetidine when R3 is -CONRi 1R12;
• R3 represents a group chosen from: (5) - (CH2) q-OH in which q is 0;
• R7, Rg, R9, Ri 1 and R12 being as defined for a compound of formula (I); in the form of a base or an addition salt with an acid, as well as with the hydrate or solvate state.
• Ar represents a 3,4-dichloro-phenyl or a 3,4-difluorophenyl
• R 1 represents a phenyl, a 4-chlorophenyl, a 4-fluorophenyl, a 3,4-difluorophenyl;
• R 2 represents: pyridin-2-yl
• R2 may further represent a piperidin-1-yl when R3 represents a group -
• K-3 represents a group chosen from: a hydroxy
• a protective group Pg is understood to mean a group that makes it possible, on the one hand, to protect a reactive function such as a hydroxyl or an amine during a synthesis and, on the other hand, to regenerate the intact reactive function. at the end of synthesis. Examples of protecting groups as well as methods of protection and deprotection are given in "Protective Group in Organic Synthesis", Green et al., 2 nd Edition (John Wiley & Sons, Inc., New York), 1991.
• leaving group is meant, in what follows, a group that can be easily cleaved from a molecule by breaking a heterolytic bond, with departure from an electronic pair. This group can thus be easily replaced by another group during a substitution reaction, for example.
• Such leaving groups are, for example, halogens or an activated hydroxy group such as methanesulfonate, benzenesulfonate, p-toluenesulfonate, triflate, acetate, etc. Examples of leaving groups as well as references for their preparation are given in "Advanced in Organic Chemistry", J. Tuesday, 3 rd Edition, Wiley Interscience, 1985, p. 310-316.
• the compounds of formula (I) can be prepared according to a process which is characterized in that: a compound of formula
• R.2 and R3 are as defined for a compound of formula (I), in the presence of an acid, in a solvent, and then the intermediate-formed iminium salt is reduced by means of a reducing agent.
• the compound of formula (I) is converted into one of its salts. "Addition to an acid.
• the reaction is carried out in the presence of an acid such as acetic acid, in a solvent such as methanol or dichloromethane, at a temperature between room temperature and the reflux temperature of the solvent, and in-situ form an intermediate imine which is reduced chemically using, for example, j, sodium cyanoborohydride or sodium triacetoxyborohydride or catalytically using hydrogen and a catalyst such as palladium on carbon or Raney nickel.
• an acid such as acetic acid
• a solvent such as methanol or dichloromethane
• R2 and R3 are as defined for a compound of formula (T).
• the compound of formula (I) is converted to one of its addition salts with an acid.
• the reaction is carried out in a solvent such as N, N-dimethylformamide, acetonitrile, dichloromethane, toluene or propan-2-ol and in the presence or absence of a base.
• a base is chosen from organic bases 35 such as triethylamine, N, N-diisopropylethylamine or N-methylmorpholine or from carbonates or alkali metal bicarbonates such as potassium carbonate, sodium carbonate or sodium bicarbonate.
• the reaction is carried out using an excess of the compound of formula (HT) and in the presence of an alkali metal iodide such as potassium iodide or sodium iodide.
• the reaction is carried out at a temperature between room temperature and 100 ° C.
• the compound of formula (I) thus obtained may be subsequently separated from the reaction medium and purified by conventional methods, for example by crystallization or chromatography.
• the oxidation reaction is carried out using, for example, oxalyl chloride, dimethylsulfoxide and triethylamine in a solvent such as dichloromethane and at a temperature between -78 ° C and room temperature.
• Ar and Rj are as defined for a compound of formula (I) and Pg represents a conventional O-protecting group such as, for example, tetrahydropyran
• deprotection is carried out according to conventional methods well known to those skilled in the art.
• deprotection is by acid hydrolysis using hydrochloric acid in a solvent such as ether, methanol or a mixture of these solvents, or using /? - toluenesulfonate in a solvent such as methanol or alternatively using an Amberlyst ® resin in a solvent such as methanol.
• the reaction is carried out at a temperature between room temperature and the reflux temperature of the solvent.
• Pg j represents a benzoyl group or a (Cl- C4) alkylcarbonyl group
• the deprotection is effected by hydrolysis in alkaline medium using for example an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide or lithium hydroxide, in a solvent such as water, methanol, ethanol, dioxane or a mixture of these solvents, at a temperature between 0 ° C. and the reflux temperature solvent.
• an alkali metal hydroxide such as sodium hydroxide, potassium hydroxide or lithium hydroxide
• the compounds of formula (VI) are prepared by cyclization of compounds of formula:
• Ar and K 1 are as defined for a compound of formula (I), Pg is as defined for a compound of formula (VT) and Hal represents a halogen atom, preferably chlorine or bromine.
• the cyclization reaction is carried out in the presence of a base such as potassium tert-butoxide in a solvent such as tetrahydrofuran and at a temperature between -60 ° C and room temperature.
• the compounds of formula (X) are prepared from triarylbismuthane of formula:
• R 1 is as defined for a compound of formula (I) according to known methods such as those described in Synthetic Communications, 1996, 26 (24),
• the compounds of formula (HT) are known or are prepared according to known methods such as those described in EP-0 428 434, EP-0 512 901, EP-0 515 240,
• the compounds of formula (DT) are generally prepared in protected form on the nitrogen atom of piperidine; after a deprotection step, the compounds of formula (IH) expected are obtained.
• R3 represents a group - (??????? -NR ⁇ CORg) in which R7 and Rg together represent a - (CH2) p- group according to SCHEME I below, in which wherein Pg2 represents an N-protecting group such as benzyl, benzyloxycarbonyl or tert-butyloxycarbonyl, HaI represents a halogen atom, preferably chlorine and R2, q and p being as defined for a compound of formula ( I).
• step a1 of SCHEME I a compound of formula (XIII) is reacted with a compound of formula (XTV) in the presence of a base such as triethylamine, in a solvent such as acetonitrile or dichloromethane, and in a temperature between 0 ° C and room temperature to obtain a compound of formula (XVI).
• a base such as triethylamine
• a solvent such as acetonitrile or dichloromethane
• step cL The cyclization, in step cL, of the compound of formula (XVI) to give the compound of formula (XVII) is carried out in the presence of a base such as hydride of sodium, in a solvent such as N, N-dimethylformamide and at a temperature between room temperature and 60 ° C.
• a base such as hydride of sodium
• a solvent such as N, N-dimethylformamide
• step dI The compound of formula (XVII) is deprotected at step dI according to the known methods to give the compounds of formula (Ii) expected.
• step a2 of SCHEMA H a compound of formula (XVIII) is reacted with a compound of formula (XX), in the presence of a base such as triethylamine, in a solvent such as dichloromethane or 1, 2-dichloroethane and at a temperature between 0 ° C. and room temperature, to obtain a compound of formula (XXH).
• a base such as triethylamine
• a solvent such as dichloromethane or 1, 2-dichloroethane and at a temperature between 0 ° C. and room temperature
• step b_2 a compound of formula (XIX) with a compound of formula (XXI), in a solvent such as 1,2-dichloroethane and at the reflux temperature of the solvent.
• step c2 of the compound of formula (XXII) to give the compound of formula (XXI) is carried out in the presence of a base such as sodium hydride, in a solvent such as N, N-dimethylformamide and at a temperature between room temperature and 60 ° C.
• a base such as sodium hydride
• a solvent such as N, N-dimethylformamide
• step d_2 The compound of formula (XXDT) is deprotected in step d_2 according to conventional methods to give the expected compound of formula (DI).
• step a3_ of the SCHEMA lu a compound of formula (XIX) is reacted with a compound of formula (XXTV) in a solvent such as 1,2-dichloroethane and at a temperature between room temperature and temperature. reflux of the solvent.
• a solvent such as 1,2-dichloroethane
• step b_3 of the compound of formula (XXV) to give the compound of formula (XXVI) is carried out in the presence of a base such as sodium hydride, in a solvent such as N, N-dimethylformamide and at a temperature between room temperature and 60 ° C.
• a base such as sodium hydride
• a solvent such as N, N-dimethylformamide
• step c3 The compound of formula (XXVI) is deprotected in step c3 according to conventional methods to give the compound of formula (Ii) expected.
• the compounds of formula (IV) are prepared by reaction of a compound of formula (V) with a compound of formula:
• Y-SO 2 -Cl in which Y represents a methyl, phenyl, tolyl or trifluoromethyl group, in the presence of a base such as triethylamine, N, N-diisopropylethylamine or pyridine, in a solvent such as dichloromethane or toluene, and at a temperature between -20 ° C and the reflux temperature of the solvent.
• a base such as triethylamine, N, N-diisopropylethylamine or pyridine
• the invention also relates to the compounds of formula (D), (IV), (V), (VI), (Vu), (VHI) and certain compounds of formula (IU) . These compounds are useful as synthesis intermediates of the compounds of formula (I).
• the subject of the invention is compounds of formula: ; in which :
• Ar represents a phenyl mono- or disubstituted with a halogen atom
• R 1 represents a phenyl which is unsubstituted or substituted once or twice with one or two substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy.
• the subject of the invention is also compounds of formula:
• Y represents a methyl, phenyl, tolyl or trifluoromethyl group
• Ar represents a phenyl mono- or disubstituted with a halogen atom
• R 1 represents a phenyl which is unsubstituted or substituted one or two times with one or two substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl or a (C 1 -C 4) alkoxy.
• Ar represents a phenyl mono- or disubstituted with a halogen atom
• R 1 represents a phenyl that is unsubstituted or substituted one or two times with one or two substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl or a (C 1 -C 4) alkoxy.
• the subject of the invention is also compounds of formula:
• - Pgj represents a radical tetrahydropyran-2-yl, benzoyl or (C j -
• Ar represents a phenyl mono- or disubstituted with a halogen atom
• R 1 represents a phenyl that is unsubstituted or substituted one or two times with one or two substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl or a (C 1 -C 4) alkoxy.
• the invention also relates to compounds of formula:
• - HaI represents a chlorine or bromine atom
• Pgi represents a tetrahydropyran-2-yl, benzoyl or (C 1 -C 4) alkylcarbonyl radical;
• . - - Ar represents a phenyl mono- or disubstituted by a halogen atom
• R 1 represents a phenyl that is unsubstituted or substituted one or two times with one or two substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy.
• the subject of the invention is also compounds of formula:
• Pgi represents a tetrahydropyran-2-yl, benzoyl or (C 1 -C 4) alkylcarbonyl radical;
• Ar represents a phenyl mono- or disubstituted with a halogen atom
• R 1 represents a phenyl that is unsubstituted or substituted one or two times with one or two substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy.
• the invention also relates to compounds of formula:
• n ⁇ - R2 represents:
• pyridyl a phenyl which is unsubstituted or substituted one or two times with one or two substituents independently selected from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy, a trifluoromethyl group, a trifluoromethoxy group; a benzyl which is unsubstituted or substituted on the phenyl one or two times with one or two substituents chosen independently from a halogen atom, a (C 1 -C 4) alkyl, a (C 1 -C 4) alkoxy, a trifluoromethyl group or a trifluoromethoxy group; ;
• R3 represents a group: (11) - (CH2) q-NR 7 COOR 9;
• q 0, 1 or 2;
• R7 and R9 together represent a group - (CH1) n -;
• n 2 or 3; in the form of a base or an acid addition salt.
• DCM dichloromethane
• AcOEt ethyl acetate
• DIPEA diisopropylethylamine
• TFA trifluoroacetic acid
• BOP benzotriazol-1-yloxytris (dimethylamino) phosphonium hexafluoro phosphate 2N hydrochloric ether: 2N solution of hydrochloric acid in diethyl ether
• Silica H silica gel 60 H marketed by Merck (DARMSTAD)
• Buffer solution pH 2: solution of 16.66 g of KHSO4 and 32.32 g of K2SO4 in 1 liter of water.
• the compounds according to the invention are analyzed by LC / UV / MS coupling (liquid chromatography / UV detection / mass spectrometry).
• the molecular peak (MH) and the retention time (tr) are measured in minutes.
• the eluent is composed as follows:
• solvent A 0.005% trifluoroacetic acid (TFA) in water at pH 3.15;
• solvent B 0.005% of TFA in acetonitrile.
• a mixture of 10 g of the compound obtained in Preparation 1.3, 5.78 g of the compound obtained in Preparation 2.3 and 0.43 g of the compound obtained in step A of Preparation 3.1 in a mixture of 10 g of the compound obtained in Preparation 1.3 are left stirring for 18 hours at RT. 500 ml of DCM. The reaction mixture is concentrated under vacuum, the residue is taken up in DCM, the insoluble material is filtered and the filtrate is chromatographed on silica gel, eluting with DCM. 5.84 g of the expected compound are obtained.
• a solution of 16 g of the compound obtained in Preparation 4.1 in 750 ml of THF is cooled to -60 ° C., 3.54 g of potassium tert-butoxide is added, the mixture is left stirring and the temperature is allowed to return to -30 ° C. then left stirring for 30 minutes at -30 ° C.
• the reaction mixture is poured into a buffer solution pH ⁇ 2 previously cooled, extracted with I 1 AcOEt, the organic phase washed with water, dried over Na 2 SO 4 and the solvent evaporated under empty. 14.85 g of the expected product are obtained.
• a solution of 1.28 g of potassium tert-butoxide in 250 ml of THF is cooled to -60 ° C. and then a solution of 6.2 g of the compound obtained in Preparation 4.3 in 40 ml is added dropwise.
• THF left stirring, allowing the temperature to rise to -30 ° C. and left stirring for 1 hour at -30 ° C.
• a solution of 2 g of potassium tert-butoxide in 450 ml of THF is cooled to -60 ° C. and then a solution of 9.5 g of the compound obtained in Preparation 4.4 in 40 ml of THF is added dropwise. leave stirring while allowing the temperature to rise to -30 ° C. and leave stirring for 1 hour at -30 ° C.
• the reaction mixture is poured into a pH 2 buffer solution, cooled beforehand, extracted with 1 AcOEt, the organic phase washed with water and with saturated NaCl solution, dried over MgSO 4 and the solvent evaporated in vacuo. 8.4 g of the expected compound are obtained.
• a solution of 1.08 g of potassium tert-butoxide in 250 ml of THF is cooled to -60 ° C., then a solution of the compound obtained in Preparation 4.5 in 40 ml of THF is added dropwise, and the mixture is stirring, allowing the temperature to rise to -30 ° C and stirring for 1 hour at -30 ° C.
• the reaction mixture is poured into a pH 2 buffer solution, cooled beforehand, extracted with 1 AcOEt, the organic phase washed with water and with saturated NaCl solution, dried over MgSO 4 and the solvent evaporated in vacuo. 4.78 g of the expected compound are obtained.
• a solution of 2.05 ml of oxalyl chloride in 80 ml of DCM is cooled to -60 ° C., a solution of 2.50 ml of DMSO in 20 ml of DCM is added dropwise, then drop, a solution of 4.7 g of the compound obtained in Preparation 6.3 and 3.5 ml of DMSO in 40 ml of DCM and left stirring for 1 hour at -60 ° C. 10.1 ml of triethylamine are then added and leave stirring while allowing the temperature to rise to RT.
• the reaction mixture was washed with 1N HCl solution, 10% Na2CO3 solution, saturated NaCl solution, dried over MgSO4 and the solvent evaporated in vacuo.
• reaction mixture is poured into a saturated solution of NH 4 Cl, extracted with ether, the organic phase is dried over Na 2 SO 4 and the solvent is evaporated under vacuum. 38.3 g of the expected product are obtained after crystallization from cyclohexane.
• This compound is prepared according to the procedure described in step A) of Preparation 8.3 from 2.6 g of magnesium in 15 ml of THF, 15 g of 1-bromo- 4-methylbenzene in 100 ml of THF and 16.6 g of 1-benzyl-4-pteridinone in 100 ml of THF. 22.9 g of the expected product are obtained.
• a solution of 44.8 g of 1-bromo-4-methoxybenzene in 700 ml of THF is cooled to -78 ° C. and 168 ml of a 1.6M solution of n-butyllithium is added dropwise to the solution. hexane and then leave stirring for 30 minutes at -78 ° C.
• a solution of 45.3 ml of 1-benzyl-4-piperidinone in 100 ml of THF is then added dropwise and the mixture is stirred for 2 hours at -78 ° C.
• the reaction mixture is poured into 400 ml of water.
• reaction mixture is poured onto ice, basified by addition of a 30% NaOH solution, the precipitate formed is filtered off and washed with water. 49.4 g of the expected product are obtained, which is used as such.
• This compound is prepared according to the procedure described in step A of Preparation 8.5 from 20 g of 1-bromo-4- (trifluoromethoxy) benzene in 300 ml of THF, 89.3 ml of a solution 1, 6M n-butyllithium in hexane and 24.1ml of 1-benzyl-4-piperidinone in 50ml of THF. 18.5 g of the expected product are obtained.
• step B) of Preparation 8.3 A mixture of 14.5 g of the compound obtained in step B) of Preparation 8.3 and 100 ml of a solution of 8% HCl is refluxed for 48 hours.
• the reaction mixture is concentrated under vacuum, the residue is taken up in ether and the precipitate formed is filtered off with suction.
• the precipitate is taken up in 10% Na2CO3 solution, extracted with DCM, the organic phase is dried over Na2SO4 and the solvent is evaporated under vacuum. 10.75 g of the expected product are obtained.
• a mixture of 20 g of the compound obtained in step A of Preparation 8.4 and 120.7 ml of 4-chlorobutyronitrile is cooled to 0 ° C., 50.5 ml of a solution of H 2 SO 4 are added dropwise. at 95% and left stirring for 2 hours at 0-5 ° C.
• the reaction mixture is poured into water, basified to pH 14 by adding a concentrated solution of NaOH, extracted with DCM, the organic phase is washed with water and dried over MgSO.sub.4 and the solvent is partially concentrated.
• a mixture of 6.8 g of the compound obtained in step A of Preparation 8.4 and 50.3 g of 5-chloro-n-valeronitrile is cooled to 0 ° C., 17.16 ml of a sodium hydroxide solution are rapidly added. 95% H 2 SO 4 and left stirring for 4 hours at 0 ° -5 ° C.
• the reaction mixture is poured into water, basified to pH 14 by addition of a concentrated solution of NaOH, extracted with DCM, the phase washed. organic to water, dried over MgSO 4 and evaporated the solvent in vacuo. The residue is taken up in a 2N solution of hydrochloric ether, stirred and the precipitate formed. 2 g of the expected product are obtained.
• This compound is prepared according to the procedure described in step A of Preparation 8.3 from 3.4 g of magnesium in 15 ml of THF, of a solution of 20 g of 1-bromo-3-methylbenzene in 100 ml. ml of THF and a solution of 22.13 g of 1-benzyl-4-piperidone in 100 ml of THF. 26.54 g of the expected product are obtained.
• This compound is prepared according to the procedure described in step A of Preparation 8.9 from 24 g of the compound obtained in the preceding step, 14.5 ml of 4-chlorobutyronitrile and 60.6 ml of a solution of 95% H2SO4. 8.3 g of the expected product are obtained.
• a mixture of 151 g of 4-phenylpiperidine-4-carboxylic acid p-toluenesulphonate and 213 g of a 30% aqueous solution of NaOH in 500 ml of water is cooled to 5 ° C.
• a solution of 68.2 g of benzyl chloroformate in 150 ml of acetone is added dropwise and the mixture is left stirring for 6 days, allowing the temperature to rise to RT.
• 150 ml of acetone are added and the reaction mixture is poured into a mixture of 200 g of concentrated HCl solution, 300 ml of water and 300 ml of acetone previously cooled in an ice bath.
• a solution of 55.3 g of the compound obtained in the preceding stage in 200 ml of acetone is cooled to 50 ° C., a solution of 19.5 g of sodium azide in 60 ml of sodium chloride is added dropwise. water and left stirring for 2 hours, allowing the temperature to rise to RT. It is concentrated under vacuum, the residue is taken up in a 5% solution of NaHCO 3, extracted with toluene, the organic phase is washed with water, with saturated NaCl solution, dried over Na 2 SO 4 and concentrated two thirds of the solvent under vacuum. The remainder of the toluene solution is refluxed for 1 hour and then concentrated in vacuo. 54 g of the expected product are obtained in the form of an orange oil which crystallizes.
• a mixture of 54.71 g of the compound obtained in the preceding step and 57 g of potassium hydroxide in 360 ml of diethylene glycol is heated at reflux for 7 hours and then left stirring overnight at RT.
• the volume of the reaction mixture is brought to 900 ml by addition of ice, neutralized to pH 7 by addition of a concentrated solution of HCl and stirred for 2 hours.
• the precipitate formed is filtered off and washed with acetone. 31.56 g of the expected product are obtained.
• a solution of 31.8 g of the compound obtained in the preceding stage in 200 ml of acetone is cooled in an ice bath and a solution of 11.1 g of sodium azide in 15 ml of water is added dropwise. and left stirring for 1 hour at RT. It is concentrated under vacuum, the residue is extracted with toluene, the organic phase is washed with a 5% solution of NaHCO 3, with saturated NaCl solution and dried over Na 2 SO 4. The resulting toluene solution is refluxed for 1 hour and then concentrated in vacuo. The residue is taken up in pentane and the precipitate formed is filtered off. 26 g of the expected product are obtained.
• reaction mixture is concentrated under vacuum, the residue is taken up in water and extracted with ether, the organic phase is dried over Na.sub.2SO.sub.4 and the solvent is evaporated under vacuum.
• the residue is taken up in a 2N hydrochloric ether solution, the precipitate formed is filtered off and washed with pentane. 18 g of the expected product are obtained, mp 265-267 ° C.
• a solution of 9 g of the compound obtained in the preceding step and 5.16 ml of triethylamine in 200 ml of acetone is cooled to 0 ° C., a solution of 3.1 g of azide of sodium in 15 ml of water and leave stirring while allowing the temperature to rise to RT. It is concentrated under vacuum, the residue is extracted with toluene, the organic phase is washed with water and dried over Na.sub.2SO.sub.4 and the toluene phase is refluxed for 3 hours. It is concentrated under vacuum and gives 4 g of the expected product which is used as it is.
• a mixture of 33 g of the compound obtained in step A of Preparation 8.8 and 18.42 g of ammonium formate in 500 ml of MeOH is cooled in an ice-bath, 0.5 g of palladium-on-carbon are added to the mixture. %, left stirring for 3 hours, allowing the temperature to rise to RT and then heated at 40 ° C. for 1 hour. We filter the r.ç. catalyst and concentrated the filtrate under vacuum. 28 g of the expected product are obtained.
• This compound is prepared according to the procedures described in Preparation 1.29 in WO 97/10211.
• This compound is prepared according to the procedure described in step B of Preparation 3.1 in WO 02/094821.
• the residue is chromatographed on silica gel H, eluting with DCM and then with the gradient of the DCM / EtOH mixture to (98/2; v / v).
• the product obtained is taken up in 2N hydrochloric ether, concentrated under vacuum, the residue is dissolved in DCM, ether is added and the precipitate formed is filtered off. 0.42 g of the expected product is obtained.
• DCM was added 0.387 g of the compound obtained in Preparation 8.2 and then 0.61 g of sodium triacetoxyborohydride and 0.0085 g of acetic acid and left stirring overnight at RT.
• the reaction mixture is basified by addition of a 10% solution of Na 2 CO 3, extracted with DCM, the organic phase is washed with water and dried over Na 2 SO 4, and the solvent is evaporated under vacuum.
• the residue is chromatographed on silica gel H, eluting with DCM and then with the gradient of the DCM / MeOH mixture to (97/3; v / v).
• the product obtained is taken up in 2N hydrochloric ether, concentrated under vacuum, the residue is dissolved in DCM, ether is added and the precipitate formed is filtered off. 0.57 g of the expected product is obtained.
• the reaction mixture is washed with a 10% solution of Na 2 CO 3, the organic phase is washed with water and dried over Na 2 SO 4 and the solvent is evaporated under vacuum.
• the residue is chromatographed on silica gel H, eluting with DCM and then with a DCM / MeOH mixture (99/1, v / v).
• the product obtained is dissolved in DCM, 2N hydrochloric ether is added, the precipitate formed is filtered off and washed with ether. 0.4 g of the expected product is obtained.
• reaction mixture is washed with a 10% solution of Na 2 CO 3, with water, dried over
• the compounds according to the invention have been the subject of pharmacological tests.
• the affinity of the compounds for the NK 2 tachykinin receptors was evaluated in vitro by measuring the inhibition of [ 125 N- ⁇ -neurokinin A ([ 125 I] Hs-NKA) binding to human NK2 cloned receptors expressed by cells.
• CHO Y. Takeda et al., J. Neurochem., 1992, 59, 740-745).
• the compounds according to the invention strongly inhibit the binding [125 ⁇ jjjj s _] y f ⁇ N & A receptor 2 human cloned and expressed in CHO cells with an inhibition constant Ki between 50 nM and 0.05 nM.
• Ki inhibition constant
• compound No. 3 has an inhibition constant (Ki) equal to 0.16 nM.
• the compounds of the present invention have also been evaluated in vivo in a pharmacodynamic model.
• the present invention relates to the use of the compounds of formula (I), or one of their pharmaceutically acceptable salts, solvates and / or hydrates for the preparation of medicaments intended to treat and to prevent any central and / or peripheral pathology where neurokinin A via its NK.2 receptor is involved.
• the compounds according to the invention can therefore be used for the preparation of medicaments, in particular antagonists of NK2 receptors of neurokinin A.
• the subject of the invention is medicaments which comprise a compound of formula (I), or an addition salt thereof to a pharmaceutically acceptable acid or a hydrate or a solvate of the compound of formula (I).
• analgesic in particular in the treatment of traumatic pains such as postoperative pains; neuralgia of the brachial plexus; chronic pain such as arthritis pain due to osteoarthritis, rheumatoid arthritis or psoriatic arthritis; neuropathic pain such as post-herpetic neuralgia, trigeminal neuralgia, segmental or intercostal neuralgia, fibromyalgia, causalgia, peripheral neuropathy, diabetic neuropathy, chemotherapy-induced neuropathies, neuropathies related to
• AIDS occipital neuralgia, geniculate neuralgia, glossopharyngeal neuralgia; pain of the illusion of amputees; various forms of headache such as chronic or acute migraine, temporomandibular pain, sinus pain maxillary, facial neuralgia, odontalgia; cancer pain; pain of visceral origin; gastrointestinal pain; pain due to nerve compression, pain due to the intensive practice of a sport; dysmenorrhea; menstrual pain; pain due to meningitis, arachnoiditis; musculoskeletal pain; lower back pain due to spinal stenosis, prolapsed disc, sciatica; pain of the angina; pain due to ankylosing spondylitis; pain related to gout; pain associated with burns, scarring, pruritic dermatitis; thalamic pain;
• an anti-inflammatory agent especially for treating inflammations in asthma, influenza, chronic bronchitis (especially chronic obstructive bronchitis, COPD of the English chromium obstructive pulmonary disease), coughs, allergies, bronchospasm and 'rheumatoid arthritis ; inflammatory diseases of the gastrointestinal system eg Crohn's disease, ulcerative colitis, pancreatitis, gastritis, inflammation of the intestines, disorders caused by non-steroidal anti-inflammatory drugs, inflammatory and secretory effects due to bacterial infections for example due to Clostridium difficile; inflammatory diseases of the skin, for example herpes and eczema; inflammatory diseases of the bladder such as cystitis and incontinence; ophthalmic inflammations such as conjunctivitis, vitreoretinopathy; dental inflammations such as gingivitis and periodontitis;
• allergic diseases in particular of the skin, such as urticaria, contact dermatitis, atopic dermatitis and respiratory diseases such as rhinitis;
• nausea and vomiting induced by drugs such as agents used in chemotherapy for cancer
• radiation therapies during irradiation of the thorax or the abdomen in the treatment of cancer, carcinoidosis; by ingestion of poison; by toxins due to metabolic or infectious disorders such as gastritis, or produced during bacterial or viral gastrointestinal infection; during pregnancy during vestibular disorders such as motion sickness, vertigo, Meniere's syndrome; during post-operative diseases; nausea and vomiting induced by dialysis, by prostaglandins; by gastrointestinal obstructions; during reduced gastrointestinal motility; visceral pain with myocardial infarction or peritonitis; during migraine; during altitude sickness; by ingestion of opioid analgesics such as morphine; during gastroesophageal reflux; during acid indigestion or overconsumption of food or drink, during acidity or gastric acid, regurgitation, heartburn, for example episodic,
• diseases of the cardiovascular system such as hypertension, vascular aspects of migraine, oedemas, thrombosis, angina pectoris, vascular spasms, circulatory diseases due to vasodilatation, Raynaud's disease , fibrosis, collagen diseases, atherosclerosis, preeclampsia;
• - demyelination diseases such as multiple sclerosis or amyotrophic lateral sclerosis
• diseases of the immune system related to the suppression or stimulation of the functions of immune cells, for example rheumatoid arthritis, psoriasis, Crohn's disease, diabetes, lupus, rejection reactions after transplantation
• urination disorders in particular pollakiuria, stress incontinence, emergency incontinence, postpartum incontinence;
• ocular disorders such as glaucoma, ocular hypertension, miosis, excess tears;
• the compounds of formula (I) are particularly useful for the treatment of irritable bowel syndrome (IBS); fibromyalgia; neuropathic pain chronic fatigue syndrome; migraine; atypical facial pain; Crohn's disease ulcerative colitis; constipation; diarrhea; gastroesophageal reflux; gastritis; pancreatitis; major depression; anxiety such as generalized anxiety, social anxiety, phobia and panic; obsessive disorders compulsive; tics; mania; bipolar disorder; schizophrenia; schizoaffective disorders; personality disorders; psychotic disorders; disorders related to deficits of attention or hyperactivity; disorders due to the use of addictive substances; hypertrophy of the prostate.
• IBS irritable bowel syndrome
• fibromyalgia neuropathic pain chronic fatigue syndrome
• migraine atypical facial pain
• Crohn's disease ulcerative colitis constipation
• diarrhea gastroesophageal reflux
• gastritis pancreatitis
• major depression anxiety such as generalized anxiety, social anxiety, phobia
• the present invention relates to pharmaceutical compositions comprising, as active principle, a compound according to the invention.
• These pharmaceutical compositions contain an effective dose of at least one compound according to the invention, or a pharmaceutically acceptable salt, a solvate or hydrate of said compound, as well as at least one pharmaceutically acceptable excipient.
• Said excipients are chosen according to the pharmaceutical form and the desired mode of administration, from the usual excipients which are known to those skilled in the art.
• compositions of the present invention for oral, sublingual, subcutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal or rectal administration the active ingredient of formula (T) above, or its salt, solvate or hydrate, may be administered in unit dosage form, in admixture with conventional pharmaceutical excipients, to animals and humans for the prophylaxis or treatment of the above disorders or diseases.
• Suitable unit dosage forms include oral forms such as tablets, soft or hard capsules, powders, granules and oral solutions or suspensions, sublingual, oral, intratracheal, intraocular, intranasal forms of administration. by inhalation, topical, transdermal, subcutaneous, intramuscular or intravenous administration forms, rectal administration forms and implants.
• the compounds according to the invention can be used in creams, gels, ointments or lotions.
• a unitary form of administration of a compound according to the invention in tablet form may comprise the following components:
• the dose of active ingredient administered per day can reach 0.01 to 100 mg / kg, in one or more doses, preferably 0.02 to 50 mg / kg.
• the dosage appropriate to each patient is determined by the physician according to the mode of administration, the weight and the response of said patient.
• the present invention also relates to a method of treatment of the pathologies indicated above which comprises the administration to a patient of an effective dose of a compound according to the invention, or one of its pharmaceutically acceptable salts or hydrates or solvates.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Psychiatry (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Physical Education & Sports Medicine (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Plural Heterocyclic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (2)

Family

ID=34951659

Family Applications (1)

Country Status (30)

Families Citing this family (2)

Citations (7)

Family Cites Families (6)

• 2004
  • 2004-07-23 FR FR0408222A patent/FR2873373B1/fr active Active
• 2005
  • 2005-07-19 PE PE2005000833A patent/PE20060553A1/es not_active Application Discontinuation
  • 2005-07-19 UY UY29022A patent/UY29022A1/es unknown
  • 2005-07-20 MY MYPI20053337A patent/MY142757A/en unknown
  • 2005-07-20 CA CA002573446A patent/CA2573446A1/fr not_active Abandoned
  • 2005-07-20 BR BRPI0513581-8A patent/BRPI0513581A/pt not_active IP Right Cessation
  • 2005-07-20 KR KR1020077001501A patent/KR20070034066A/ko not_active Application Discontinuation
  • 2005-07-20 CN CN2005800286192A patent/CN101006084B/zh not_active Expired - Fee Related
  • 2005-07-20 UA UAA200701878A patent/UA86082C2/ru unknown
  • 2005-07-20 EP EP05790796.6A patent/EP1773823B1/fr active Active
  • 2005-07-20 MX MX2007000814A patent/MX2007000814A/es active IP Right Grant
  • 2005-07-20 AU AU2005276352A patent/AU2005276352A1/en not_active Abandoned
  • 2005-07-20 WO PCT/FR2005/001852 patent/WO2006021654A1/fr active Application Filing
  • 2005-07-20 JP JP2007521987A patent/JP4812759B2/ja not_active Expired - Fee Related
  • 2005-07-20 GT GT200500196A patent/GT200500196A/es unknown
  • 2005-07-20 ZA ZA200700603A patent/ZA200700603B/xx unknown
  • 2005-07-20 EA EA200700098A patent/EA011035B1/ru not_active IP Right Cessation
  • 2005-07-21 PA PA20058640101A patent/PA8640101A1/es unknown
  • 2005-07-21 AR ARP050103016A patent/AR050262A1/es unknown
  • 2005-07-21 HN HN2005000380A patent/HN2005000380A/es unknown
  • 2005-07-22 SV SV2005002176A patent/SV2006002176A/es not_active Application Discontinuation
  • 2005-07-22 TW TW094124977A patent/TW200603800A/zh unknown
• 2006
  • 2006-12-26 TN TNP2006000438A patent/TNSN06438A1/fr unknown
• 2007
  • 2007-01-01 IL IL180484A patent/IL180484A0/en unknown
  • 2007-01-09 US US11/621,224 patent/US7521449B2/en not_active Expired - Fee Related
  • 2007-01-09 CR CR8843A patent/CR8843A/es unknown
  • 2007-01-17 EC EC2007007181A patent/ECSP077181A/es unknown
  • 2007-01-17 MA MA29619A patent/MA28741B1/fr unknown
  • 2007-02-22 NO NO20071020A patent/NO20071020L/no not_active Application Discontinuation
  • 2007-11-22 HK HK07112751.7A patent/HK1107340A1/xx not_active IP Right Cessation

Patent Citations (7)

Also Published As

Similar Documents

Legal Events